375
Participants
Start Date
April 30, 2014
Primary Completion Date
October 31, 2014
Study Completion Date
January 31, 2015
Placebo
Oral placebo capsule
PRC-063 25 mg
Oral 25 mg capsule - active
PRC-063 45 mg
Oral 45 mg capsule - active
PRC-063 70 mg
Oral 70 mg capsule - active
PRC-063 100 mg
Oral 100 mg capsule - active
Medical Research Network, New York
NeuroScience, Herndon
Wake Research Associates, Raleigh
CNS Healthcare Jacksonville, Jacksonville
Sarkis Clinical Research, Gainesville
Sarkis Clinical Trials, Gainesville
Florida Clinical Research Center, Maitland
Clinical Neuroscience Solutions, Orlando
Stedman Clinical Trials, Tampa
Florida Clinical Research Center, Bradenton
Clinical Neuroscience Solutions Inc., Memphis
University of Cincinnati, Cincinnati
IPS Research Company, Oklahoma City
FutureSearch Trials of Dallas, L.P., Dallas
Bayou City Research Ltd, Houston
Red Oak Psychiatry Associates, Houston
Houston Clinical Trials, Houston
FutureSearch Clinical Trials, L.P., Austin
Westex Clinical Investigations, Lubbock
Advanced Clinical Research, Boise
Ericksen Research, Clinton
Physiciatric and Behavioral Solutions, Salt Lake City
Center for Psychiatry and Behavioral Medicine Inc., Las Vegas
UCLA, Los Angeles
Synergy Clinical Research, National City
Newport Beach Clinical Research Associates, Inc., Newport Beach
Oregon Center for Clinical Investigation, Portland
Orange County Neuro Phychiatry Research Centre, Orange
Oregon Center for Clinical Investigation, Salem
Northwest Clinical Research Center, Bellevue
Eastside Therapeutic Resource, Kirkland
Princeton Medical Institute, Princeton
Woodstock Research Center at Neuropsychiatric Associates, Woodstock
Dr. Margaret Weiss, Vancouver
Doctors Jackiewicz Professional Medical Corporation, Niagara Falls
Dr. Judy van Stralen, Ottawa
The Kids Clinic, Whitby
Diex Research Sherbrooke Inc., Sherbrooke
Purdue Pharma, Canada
INDUSTRY
Rhodes Pharmaceuticals, L.P.
INDUSTRY